Previous 10 | Next 10 |
Pgiam/iStock via Getty Images Thought the COVID worries were over? Not quite. Renewed concerns about variants of the disease weighed on airline stocks on Thursday. This included declines in shares of Spirit Airlines (SAVE), United (UAL) and Delta (DAL). Elsewhere on the transportation front, ...
selvanegra/iStock via Getty Images The recent approval of Biogen's ([[BIIB]] +1.0%) Aduhelm (aducanumab) has led to a "recalibration of Alzheimer's players," prompting Maxim to boost price targets for Cassava Sciences ([[SAVA]] +2.2%), Annovis Bio ([[ANVS]] -4.2%), and INmune Bio ([[INMB...
Daxus/iStock Unreleased via Getty Images Pharmaceutical companies, public and private payers, and doctors will meet later this month at the Duke-Margolis Center for Health Policy to discuss coverage determinations and evidence challenges for Alzheimer's drugs, Endpoints News reports. The cent...
Companies engaged in developing therapies for Alzheimer's disease were among the best performing biotech stocks in the first half of the year.Cassava Sciences ([[SAVA]] -1.7%) was the best performing biotech stock in the half, with a return in the period of 1166%.A phase 3 trial of its Alzhei...
Berwyn, Pennsylvania--(Newsfile Corp. - July 2, 2021) - Annovis Bio, Inc. (NYSE American: ANVS), ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, with data from two phase 2 s...
Berwyn, Pennsylvania--(Newsfile Corp. - July 1, 2021) - Annovis Bio, Inc. (NYSE American: ANVS), ("Annovis" or the "Company"), a clinical-stage drug platform company that addresses Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, with data from two phase...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biogen (NASDAQ: BIIB ) stock has been one of the few drug stocks that have lit up the investment world recently. The approval by U.S. regulators of its novel Alzheimer’s drug Aduhelm sent its shares soaring. ...
Berwyn, Pennsylvania--(Newsfile Corp. - June 24, 2021) - Annovis Bio, Inc. (NYSE American: ANVS), ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced its CEO, Ma...
The results of future clinical trials may have some slight bearing on Biogen's stock value. If several restrictions are put on the coverage of Biogen's Aduhelm, that would negatively impact the stock to some degree. Biogen's stock value would drop further if others in the Alzheime...
Annovis Bio Inc. (NYSE American:ANVS) traded today at a new 52-week high of $100.65. This new high was reached on below average trading volume as 505,000 shares traded hands, while the average 30-day volume is approximately 2.4 million shares. In the past 52 weeks, Annovis Bio Inc. share...
News, Short Squeeze, Breakout and More Instantly...
Annovis Bio (NYSE: ANVS) , a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today announced the receipt of U.S. Patent No. 12,042,482. The patent ...
MALVERN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’...
The new executive team includes Mark White, Alexander Morin, Hilda Maibach, and Blake Jensen These additions are pivotal as the company makes strides toward bringing flagship drug candidate buntanetap closer to New Drug Application (“NDA”) status and to market Annovis Bio (NYS...